Critical Path Institute

What Critical Path Institute does

Critical Path Institute (C-Path) is a US-headquartered nonprofit founded in 2005 under the FDA's Critical Path Initiative, operating as an independent public-private partnership that convenes pharmaceutical companies, regulators (FDA, EMA, PMDA), academic institutions, and patient advocacy organizations to generate drug development tools. The organization runs 26 active programs spanning neuroscience (Alzheimer's, Parkinson's, Huntington's, rare neurodegenerative diseases), rare and orphan diseases (Duchenne muscular dystrophy, polycystic kidney disease, Friedreich's ataxia, Niemann-Pick), pediatrics, tuberculosis, type 1 diabetes, and transplantation. Its core outputs are regulatory-grade drug development tools — including the first FDA/EMA-endorsed computational trial simulator for Alzheimer's disease, the first imaging biomarker qualified for polycystic kidney disease trials, and 40+ total regulatory endorsements across FDA, EMA, and PMDA, more than any other organization globally.

C-Path's technical platform comprises cloud-based data and analytics infrastructure built on CDISC SDTM standards, integrating over 700,000 standardized patient records across multiple therapeutic areas. Key products include the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP), the CPP Integrated Parkinson's Database (600+ variables), TB-APEX/TB-PACTS for tuberculosis, MSOAC's placebo database (2,465 MS patient records), and the Duchenne Regulatory Science Consortium Database. Quantitative tools include clinical trial simulation platforms (Alzheimer's disease, T1D, DMD), enrichment tools (pre-dementia Alzheimer's, early motor Parkinson's DAT, islet autoantibody T1D), and the Quantitative Medicine Program implementing model-informed drug development. The organization also operates the Patient-Centered Evidence Consortium, eCOA Consortium, PSTC (Predictive Safety Testing Consortium, est. 2006), and newer initiatives including NAMs-DC (2026) and One to Millions (2026).

C-Path's revenue model combines consortium membership fees (recurring payments from pharma, biotech, and technology firms participating in collaborative programs), public-sector grants (FDA contracts, Horizon Europe, Flinn Foundation, Science Foundation Arizona), private foundation support (Michael J. Fox Foundation, Parkinson's UK), and individual donations. Pricing is not publicly disclosed; the organization operates two offices (Tucson, AZ and Amsterdam, Netherlands) with distributed European staff across Ireland, the UK, and Cyprus, serving a global client base of drug developers and regulators.

Name

Critical Path Institute

Legal name

Critical Path Institute

Website

https://c-path.org

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

11–50 employees

Short description

Critical Path Institute is a nonprofit public-private partnership that convenes pharmaceutical firms, regulators, and patient groups to generate FDA/EMA-endorsed drug development tools, biomarkers, and standardized data platforms across 26 therapeutic areas, with 40+ regulatory endorsements globally.

Ownership category

akta.pro rank

Product category

Regulatory Science and Drug Development Tools

NAICS

Other Scientific and Technical Consulting Services (54169)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)

akta.pro secondary industries

Electronic Data Capture (EDC) Platforms (HLACAOAA), Data Management, Reporting & Regulatory Submissions for Central Labs (HLAGAEAL)

Keywords

• Regulatory science services
• Clinical trial simulation tools
• Drug development data platforms
• Biomarker qualification programs
• Clinical outcome assessments

Headquarters

HQ city

Tucson

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Others

Revenue model

1. Donations and Grants: C-Path operates as a nonprofit organization funded through donations, grants, and public-private partnership contributions. The organization accepts donations through its website and has received grants from organizations including FDA, Science Foundation Arizona, Flinn Foundation, and others.
2. Membership Fees: Consortia and coalitions such as NAMs-DC operate on membership fee structures where pharmaceutical companies, biotech companies, and other stakeholders pay to participate in collaborative development efforts.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels12 records

Core offering

Critical Path Institute is a nonprofit organization that convenes pharmaceutical companies, biotech firms, regulators, academics, and patient advocates to co-create regulatory-grade drug development tools. It builds clinical trial simulation and enrichment tools, standardized patient-level databases, biomarker qualification packages, and electronic clinical outcome assessments that are submitted to the FDA, EMA, and PMDA for formal endorsement. The organization operates multiple consortia (including Critical Path for Parkinson's, Critical Path for Alzheimer's Disease, and the Rare Disease Clinical Outcome Assessment Consortium) and runs cloud-based data platforms such as RDCA-DAP, TB-PACTS, TB-APEX, and PAN-TB.

Product overview

Critical Path Institute is a nonprofit organization that serves as a neutral public-private partnership catalyst for accelerating drug development. The organization operates a portfolio of specialized programs, consortia, tools, and data platforms that work together to address specific unmet needs across therapeutic areas. The core offerings include: clinical trial simulation and enrichment tools (for Alzheimer's, Parkinson's, Duchenne Muscular Dystrophy, and Type 1 Diabetes); data collaboration platforms and databases (RDCA-DAP, CPAD Database, PKDOC, MSOAC, CPP Integrated Parkinson's Database, FA-ICD); clinical outcome assessment programs and resources; and regulatory science initiatives. The organization also manages a network of therapeutic-focused consortia including Critical Path for Parkinson's, Critical Path for Alzheimer's Disease, CP-RND, D-RSC, Huntington's Disease RSC, PSTC, T1D Consortium, and International Neonatal Consortium. Additional programs include the One to Millions initiative (for advanced therapies) and NAMs-DC (for new approach methodologies). C-Path was created under FDA's Critical Path Initiative in 2005 and operates from headquarters in Tucson, Arizona and Amsterdam, Netherlands. Core competencies span Data Management and Standards, Biomarkers, Modeling and Analytics, Regulatory Science, and Clinical Outcome Assessments.

Differentiator

Problem solved

Functional benefit

Products and services

• Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP) Cloud-based platform promoting sharing of existing patient-level data and standardization of new data collection for rare disease research. Integrates data for analytics to accelerate understanding of disease progression, clinical outcome measures, biomarkers, and facilitates development of mathematical models and innovative clinical trial designs.
• TB-PACTS (Tuberculosis Clinical Trials Data Platform) Platform for curation and standardization of Phase III tuberculosis clinical trial data, making individual patient-level data from REMoxTB, RIFAQUIN, and OFLUTUB trials publicly available to qualified researchers.
• TB-APEX (TB Preclinical Experiments Data Platform) Platform designed to catalyze and accelerate TB research by curating and standardizing preclinical study data and making it publicly available to qualified researchers.
• PAN-TB Collaboration Platform Platform for curation and standardization of pharmacokinetic and relapsing mouse model study data, making preclinical combination studies publicly available to qualified researchers.
• Alzheimer's Pre-dementia Clinical Trial Enrichment Tool A quantitative clinical trial enrichment tool to help optimize clinical trial design in the pre-dementia stages of Alzheimer's disease, using CDR-SB as the primary endpoint. Based on a disease progression model integrating baseline hippocampal volume, patient drop-out effects, and relevant sources of variability.
• Alzheimer's Disease Clinical Trial Simulation Tool A clinical trial simulation tool to help optimize clinical trial design for mild and moderate Alzheimer's disease, using ADAS-cog as the primary cognitive endpoint. Based on a drug-disease-trial model describing disease progression, drug effects, dropout rates, placebo effect, and relevant sources of variability.
• DMD Clinical Trial Simulation Tool Developed by the Duchenne Regulatory Science Consortium (D-RSC), this tool optimizes clinical trial design of efficacy studies for potential DMD therapies by modeling longitudinal changes in functional test completion velocities.
• Early Motor Parkinson's DAT Clinical Trial Enrichment Tool A quantitative clinical trial enrichment tool to help optimize clinical trial design in the early-motor stages of Parkinson's disease, using MDS-UPDRS part III as the primary endpoint. Includes a cloud-based GUI for user-friendly simulations.
• Islet Autoantibody Clinical Trial Enrichment Tool A quantitative clinical trial enrichment tool to optimize trial design for therapies to prevent or delay T1D diagnosis, using islet autoantibodies with other relevant clinical features to increase trial power relative to unenriched trials.
• Critical Path for Alzheimer's Disease (CPAD) Database Contains demographic information, APOE4 genotype, concomitant medications, and cognitive scales (MMSE, ADAS-Cog). Includes remapped data to CDISC SDTM v3.1.2 standard.
• CPP Integrated Parkinson's Database Comprehensive collection of observational and clinical studies containing integrated and standardized data from PD observational studies and randomized clinical trials with thousands of anonymized participant records covering over 600 variables.
• Critical Path for Parkinson's (CPP) Consortium A global public-private partnership initiated in 2015 consisting of industry, nonprofit organizations, academic partners, and advisors (FDA, EMA, NIH) with the goal of accelerating approval of therapies for Parkinson's disease through drug development tools.
• Predictive Safety Testing Consortium (PSTC) Pioneering consortium formed in 2006 with pharma companies and FDA for regulatory qualification of safety biomarkers across multiple organ systems.
• PCE Consortium Measures and Licensing Platform The Patient-Centered Evidence Consortium maximizes impact of patient-centered evidence on drug development through rigorous scientific methods, standards, and multistakeholder collaboration. Provides information on available measures covering different therapeutic areas.
• Rare Disease Clinical Outcome Assessment Resource An initiative of C-Path's Rare Disease COA Consortium providing information on published COAs with potential to support efficacy endpoints in rare disease treatment trials.
• New Approach Methodologies Developer Coalition (NAMs-DC) Coalition bringing together companies developing NAMs to advance adoption, validation, and qualification of new approach methodologies including complex in vitro and in silico studies for drug discovery and development.
• One to Millions Initiative New initiative launched in 2026 to modernize how advanced therapies (antisense oligonucleotides, gene editing, RNA therapies, cell-based therapies) are developed, evaluated, and reimbursed, creating a scalable framework from individualized breakthroughs to global solutions.
• Translational Therapeutics Accelerator (TRxA) Initiative supporting academic investigators working to advance drug development projects.
• C-Path Europe European nonprofit headquarters based in Amsterdam, Netherlands pursuing complementary opportunities to bolster existing and new partnerships with European stakeholders, focusing on global regulatory science alignment.

Quantifiable outcome

• First new treatment and regimen for tuberculosis in more than 50 years
• +4 more outcomes

Named customers12 records

Segments6 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature8 records

Partnerships

50 partnerships are on record, tiered core and minor.

• Parkinson's UKcoreStrategic or Co-development Partner · 1 January 2015Founding partner of Critical Path for Parkinson's consortium in 2015. Provided generous support to establish the global public-private partnership focused on accelerating the path to approval of therapies for Parkinson's disease.
• AbbViecoreStrategic or Co-development PartnerMember of Critical Path for Parkinson's consortium contributing to drug development tool creation.
• BayercoreStrategic or Co-development PartnerMember of Critical Path for Parkinson's consortium.
• BiogencoreStrategic or Co-development PartnerMember of Critical Path for Parkinson's consortium.
• NovartiscoreStrategic or Co-development PartnerMember of Critical Path for Parkinson's consortium.
• F. Hoffmann-LaRoche Ltd.coreStrategic or Co-development PartnerMember of Critical Path for Parkinson's consortium.
• Sanofi GenzymecoreStrategic or Co-development PartnerMember of Critical Path for Parkinson's consortium.
• UCBcoreStrategic or Co-development PartnerMember of Critical Path for Parkinson's consortium.
• The Michael J. Fox Foundation for Parkinson's ResearchcoreStrategic or Co-development PartnerNonprofit organization collaborating on Parkinson's research within the CPP consortium.
• European Medicines Agency (EMA)coreStrategic or Co-development PartnerRegulatory agency partner providing guidance and endorsement of drug development tools. Has issued qualification opinions, letters of support, and endorsements for C-Path developed tools.
• U.S. Food and Drug Administration (FDA)coreStrategic or Co-development PartnerPrimary regulatory partner operating under a formal Memorandum of Understanding. FDA partners with C-Path to materialize the FDA's Critical Path Initiative mission.
• World Health Organization (WHO)coreStrategic or Co-development PartnerSelected C-Path to host TB clinical trials data. C-Path participates in WHO GAP-f project for pediatric formulations.
• Innovative Health Initiative (IHI)coreStrategic or Co-development PartnerC-Path collaborates on projects funded under IMI JU2 within the AMR Accelerator programme for tuberculosis treatment development.
• Horizon EuropecoreStrategic or Co-development PartnerEuropean funding programme supporting C-Path's participation in ERDERA and More-EUROPA projects.
• European Joint Programme on Rare Diseases (EJPRD)coreStrategic or Co-development PartnerC-Path partners in this EU programme focused on rare disease research coordination.
• EMA Regulatory Science StrategycoreStrategic or Co-development PartnerC-Path engages with EMA's Regulatory Science Research Needs initiative.
• Newcastle UniversitycoreStrategic or Co-development PartnerAcademic institution collaborating as part of Critical Path for Parkinson's consortium.
• Radboud UniversitycoreStrategic or Co-development PartnerAcademic institution collaborating on Parkinson's research.
• University of CambridgecoreStrategic or Co-development PartnerAcademic partner in Critical Path for Parkinson's consortium.
• University of OxfordcoreStrategic or Co-development PartnerAcademic partner in Critical Path for Parkinson's consortium.
• UNITE4TB PartnershipcoreStrategic or Co-development PartnerAcademia and Industry United Innovation and Treatment for Tuberculosis project, a public-private initiative C-Path participates in as work package lead for data management.
• ERA4TBcoreStrategic or Co-development PartnerEuropean Regimen Accelerator for Tuberculosis project with over 30 organizations developing drugs against TB. C-Path leads data and pipeline management.
• PAN-TB CollaborationcoreStrategic or Co-development PartnerProject to Accelerate New Treatments for Tuberculosis leveraging collective resources to identify and evaluate new drug regimens.
• Rare Disease MoonshotcoreStrategic or Co-development PartnerCoalition promoting integration of regulatory science in rare disease public-private partnerships.
• ERDERAcoreStrategic or Co-development PartnerEuropean Rare Disease Research Alliance funded through Horizon Europe.
• More-EUROPAcoreStrategic or Co-development PartnerProject supporting efficient use of real-world data in medicinal product development in Europe.
• CN BiocoreTechnology or IntegrationMember of NAMs-DC coalition developing new approach methodologies for drug discovery.
• Crown BiosciencecoreTechnology or IntegrationMember of NAMs-DC coalition. Joined in July 2026.
• EmulatecoreTechnology or IntegrationMember of NAMs-DC coalition developing organ-on-a-chip and other human-relevant testing methods.
• InSpherocoreTechnology or IntegrationMember of NAMs-DC coalition developing 3D cell models and liver disease models.
• Curi BiocoreTechnology or IntegrationMember of NAMs-DC coalition.
• ModeluscoreTechnology or IntegrationMember of NAMs-DC coalition.
• Revalia BiocoreTechnology or IntegrationMember of NAMs-DC coalition.
• VivoSpherecoreTechnology or IntegrationMember of NAMs-DC coalition.
• Movement Disorders SocietycoreStrategic or Co-development PartnerNonprofit organization collaborating as part of Critical Path for Parkinson's.
• Parkinson's FoundationcoreStrategic or Co-development PartnerNonprofit organization supporting Parkinson's research and patient care.
• Davis Phinney FoundationcoreStrategic or Co-development PartnerNonprofit organization focused on Parkinson's research and quality of life.
• Parkinson's EuropecoreStrategic or Co-development PartnerEuropean Parkinson's patient advocacy organization.
• National Institute of Neurologic Diseases and Stroke (NINDS)coreStrategic or Co-development PartnerU.S. government agency supporting neurological research.
• University of ArizonacoreStrategic or Co-development PartnerFounding partner and academic institution. C-Path established under auspices of FDA's Critical Path Initiative with support from University of Arizona. Hosts graduate certificate program in regulatory science.
• Annovis BiominorStrategic or Co-development PartnerMember of Critical Path for Parkinson's consortium.
• AskBiominorStrategic or Co-development PartnerMember of Critical Path for Parkinson's consortium.
• BiohavenminorStrategic or Co-development PartnerMember of Critical Path for Parkinson's consortium.
• BlueRock TherapeuticsminorStrategic or Co-development PartnerMember of Critical Path for Parkinson's consortium.
• CLARIOminorStrategic or Co-development PartnerMember of Critical Path for Parkinson's consortium.
• IXICOminorStrategic or Co-development PartnerMember of Critical Path for Parkinson's consortium.
• Merck Sharp and Dohme (MSD)minorStrategic or Co-development PartnerMember of Critical Path for Parkinson's consortium.
• Neuron23minorStrategic or Co-development PartnerMember of Critical Path for Parkinson's consortium.
• Octave BioScienceminorStrategic or Co-development PartnerMember of Critical Path for Parkinson's consortium.
• Vanqua BiominorStrategic or Co-development PartnerMember of Critical Path for Parkinson's consortium.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• TransCelerate BioPharma: Precompetitive pharma-funded collaboration solving common drug development challenges (clinical data standards, protocol design, safety). Most direct peer — same consortium model, overlapping pharma member base, and competing for the same precompetitive convener role.
• Foundation for the National Institutes of Health (FNIH): 501(c)(3) nonprofit that convenes NIH, FDA, industry, and academia around precompetitive biomedical partnerships (e.g., AMP, Biomarkers Consortium). Closest functional analog as a neutral public-private partnership catalyst.
• Reagan-Udall Foundation for the FDA: Independent nonprofit created by Congress to support FDA's regulatory science mission through public-private collaboration. Closest peer in mission (regulatory science advancement) and structural form (FDA-affiliated nonprofit).
• Innovative Health Initiative (IHI): EU public-private partnership (successor to IMI) funding cross-sector health research consortia. Direct peer in Europe — C-Path participates in IHI projects as a partner.
• Clinical Data Interchange Standards Consortium (CDISC): Standards organization developing CDISC SDTM data standards used in clinical research — C-Path applies CDISC standards in its data platforms and co-launched the CFAST initiative with CDISC. Tightly coupled technical peer.

Broad incumbents

• IQVIA: Largest global CRO and clinical trial technology vendor offering trial design, EDC, and real-world data at commercial scale. Overlaps C-Path's data and trial-simulation functions but as a broad, for-profit portfolio rather than a neutral nonprofit specialist.
• Parexel: Global CRO providing clinical trial design, modeling & simulation, and regulatory consulting. Comparable in trial-simulation and regulatory-science offerings; competes for the same pharma services wallet.

Others

• Bill & Melinda Gates Foundation: Large philanthropic funder that has historically supported precompetitive global-health R&D (TB, malaria, vaccines). Adjacent funder/ecosystem peer rather than direct competitor — overlaps in TB and global health agendas.
• EFGCP (European Forum for Good Clinical Practice): European nonprofit working on GCP, regulatory science, and trial methodology best practices. Adjacent ecosystem peer focused on European regulatory practice standards.
• BIO (Biotechnology Innovation Organization): Largest US biotech trade association. While not a direct service provider, BIO convenes industry voices on regulatory policy in a manner analogous to C-Path's precompetitive-consortium role.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/cpathinstitute
• YouTubeyoutube.com/channel/UCxJq_80G3cJR2MazzjJK4-A/featured
• Facebookfacebook.com/CPathInstitute
• LinkedInlinkedin.com/company/c-path

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Critical Path Institute